Bukwang to start preclinical trial for new VEGF inhibitor

Published: 2009-10-06 06:56:00

Updated: 2009-10-06 06:56:00

Bukwang Pharm said on September 28 it will commence animal experiments for apatinib mesylate, a novel Vascular Endothelial Growth Factor (VEGF) inhibitor and complete the tests in the first half of next year.

To this end, the company signed a contract study agreement with two domestic and fore...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK